AWARD OUTCOME
What happened
NHS England has announced a pending award under its Tafamidis framework to CIPLA (EU) LIMITED and PFIZER LIMITED. The single award covers lot 1, but the notice does not allocate value between the two suppliers. A future signature date is scheduled for 27 October 2026.
Published outcomeAward decision announced; not evidenced as signed or active. Award status is pending and the standstill period ended on 13 October 2026.
Market significanceThe framework concerns pharmaceutical products for delivery across several English regions, with a published award amount of £62.393m excluding VAT (£74.872m gross).
AWARDED SUPPLIERS AND LOTS
2 supplier records analysed
CIPLA (EU) LIMITED
99% confidenceAward 1 · Lots 1 · Shared award value not allocated by supplier GBP · Pending awardee
View supporting evidence
Verified company number 04513292; award 1 lists source supplier "Cipla" and includes both suppliers without individual allocations.
PFIZER LIMITED
99% confidenceAward 1 · Lots 1 · Shared award value not allocated by supplier GBP · Pending awardee
View supporting evidence
Verified company number 00526209; award 1 lists source supplier "Pfizer Ltd" and includes both suppliers without individual allocations.
LIFECYCLE
Award or contract stage
Notice status
99% confidenceAwarded opportunity; underlying award status pending
View supporting evidence
Process display_status is "awarded"; award 1 status is "pending".
Award decision date
99% confidence29 September 2026
View supporting evidence
Award 1 date is 2026-09-29.
Standstill end
99% confidence13 October 2026, 23:59:59 BST
View supporting evidence
Award 1 standstillPeriod.endDate is 2026-10-13T23:59:59+01:00.
Scheduled signature date
98% confidence27 October 2026
View supporting evidence
Award milestone futureSignatureDate is scheduled for 2026-10-27T23:59:59Z.
Contract commencement
98% confidencePlanned for 1 April 2027
View supporting evidence
Award contractPeriod.startDate is 2027-04-01; this is a planned period, not evidence of commencement.
VALUES
Published values explained
Award value excluding VAT
99% confidence£62,393,000
View supporting evidence
Award 1 value.amount is 62393000 GBP.
Award value including VAT
99% confidence£74,871,600
View supporting evidence
Award 1 value.amountGross is 74871600 GBP.
Supplier allocation
99% confidenceNot published
View supporting evidence
The single award names two suppliers but contains no supplier-level value allocation.
Process maximum value
92% confidence£65,281,000
View supporting evidence
Process value_max is 65281000 GBP; its relationship to the amended award value is not stated.
TIMELINE
Procurement timeline
Pipeline notice published
98% confidence23 April 2026
View supporting evidence
Release history records release 036871-2026 on 2026-04-23.
Preliminary market engagement notice published
98% confidence8 May 2026
View supporting evidence
Release history records release 042203-2026 on 2026-05-08.
Tender notice published
99% confidence31 July 2026
View supporting evidence
Release history records tender releases 072504-2026 and 072508-2026 on 2026-07-31.
Tender deadline
99% confidence31 August 2026, 13:00 BST
View supporting evidence
Process submission_deadline is 2026-08-31T13:00:00+01:00.
Assessment summaries sent
98% confidence2 October 2026
View supporting evidence
Award assessmentSummariesDateSent is 2026-10-02.
Award notice update published
99% confidence13 October 2026
View supporting evidence
Award document 096493-2026 datePublished is 2026-10-13T12:07:24+01:00.
SCOPE
What was awarded
Requirement
99% confidenceNHS National Framework for Tafamidis
View supporting evidence
Process and award title state "NHS National Framework for Tafamidis".
Lot structure
99% confidenceOne lot (lot 1); no published lot title or description
View supporting evidence
Tender and award relate to lot 1; supplied lot record has null title and description.
Product classification
99% confidencePharmaceutical products (CPV 33600000)
View supporting evidence
Award item additional classification is CPV 33600000, Pharmaceutical products.
Geographic delivery coverage
96% confidenceNorth East, North West, East Midlands, West Midlands, East of England, South East and South West England
View supporting evidence
Award delivery addresses list UKC, UKD, UKF, UKG, UKH, UKJ and UKK.
Amendment
99% confidenceAward made for wild-type Tafamidis; values amended to reflect the change
View supporting evidence
Award amendment states: "Award made for wild-type Tafamidis. Values amended to reflect the change."
PROCEDURE
Procedure and competition
Procedure
99% confidenceOpen procedure
View supporting evidence
Tender procurementMethodDetails is "Open procedure".
Framework arrangement
99% confidenceFramework agreement
View supporting evidence
Tender techniques.hasFrameworkAgreement is true.
Tenderers named in source
90% confidence8 tenderers, including the 2 pending awardees
View supporting evidence
Parties list eight organisations with the tenderer role: Cipla, Pfizer Ltd, Accord-UK Ltd, Lupin Healthcare (UK) Limited, Mylan / Viatris UK Healthcare Limited, Oranda Therapeutics and Thornton and Ross Ltd; Cipla and Pfizer are also suppliers.
Evaluation detail
99% confidenceNot published in supplied notice data
View supporting evidence
No scores, ranking, pricing, or selection rationale are supplied.
CONTRACT TERMS
Published contract terms
Initial framework period
99% confidence1 April 2027 to 31 May 2028 (14 months)
View supporting evidence
Tender description and award contractPeriod specify these dates.
Extension option
99% confidenceAt NHS England's discretion, up to 24 months in total
View supporting evidence
Award renewal description states extensions may total up to 24 months.
Maximum potential end date
99% confidence31 May 2030
View supporting evidence
Award contractPeriod.maxExtentDate is 2030-05-31.
COMMERCIAL VIEW
Commercial observations
Award structure
90% confidenceTwo suppliers are named on one lot and one pending award, suggesting a multi-supplier framework arrangement; allocation or call-off mechanics are not published.
View supporting evidence
Award 1 names CIPLA (EU) LIMITED and PFIZER LIMITED and relates only to lot 1; no allocation mechanism is supplied.
Value change
99% confidenceThe award notice reports amended values following an award for wild-type Tafamidis.
View supporting evidence
Award amendment explicitly links the value amendment to wild-type Tafamidis.
DATA QUALITY
Gaps and source limitations
Pending award status
99% confidenceThe notice is an award announcement, but the award remains pending and signature is only scheduled; it must not be treated as a signed or active contract.
View supporting evidence
Award status is pending and futureSignatureDate is scheduled for 27 October 2026.
Shared value
99% confidenceThe published award value covers both named suppliers and cannot be assigned to either supplier individually.
View supporting evidence
One award contains two suppliers with no supplier-level value breakdown.
Supplier name normalisation
99% confidenceThe source party name "Cipla" differs from the verified legal name CIPLA (EU) LIMITED; the verified legal name is used in this analysis.
View supporting evidence
Supplier verification identifies a name mismatch and matches company number 04513292.
Lot detail
99% confidenceLot 1 has no published title, description or separate value in the supplied data.
View supporting evidence
Supplied lot record has null title, description and value.
SOURCE DATA LIMITATIONS
Information not supplied in the published notice
- Information not supplied in the published notice: award evaluation scores, tender prices, reasons for supplier selection, bid ranking and award allocation methodology.
- Information not supplied in the published notice: supplier-specific values, volumes, pricing, call-off commitments or market-share allocation.
- Information not supplied in the published notice: a lot title, lot description and stand-alone lot value for lot 1.
- The process maximum value (£65.281m) differs from the amended award value (£62.393m excluding VAT); the source does not explain the relationship.
- The source identifies a future signature date but provides no evidence that signature, contract conclusion or service commencement has occurred.
MARKET THEMES
Relevant award themes
NHS National Framework for TafamidisNHS EnglandCIPLA (EU) LIMITEDPFIZER LIMITEDTafamidis frameworkpharmaceutical productsFind a Tender
COMMON QUESTIONS
About this award
Who are the named suppliers on the NHS Tafamidis framework award?
The pending award names CIPLA (EU) LIMITED and PFIZER LIMITED for lot 1.
What is the value of the Tafamidis framework award?
The published award value is £62.393m excluding VAT and £74.872m including VAT. It is not allocated between the two named suppliers.
Has the Tafamidis framework been signed?
The supplied data does not evidence signature. The award is pending, with a signature date scheduled for 27 October 2026.
When is the framework planned to run?
The published initial period is 1 April 2027 to 31 May 2028, with discretionary extensions of up to 24 months in total.
ProcuraAxis award analysis supplements, but does not replace, the official award notice, contract data or procurement documents. “Awarded” does not by itself prove that a contract has been signed.